Nouri Neamati

Nouri Neamati is the John G. Searle Professor of Medicinal Chemistry at the University of Michigan College of Pharmacy. He earned a Ph.D. in biomedical sciences from the University of Texas Graduate School of Biomedical Sciences and M.D. Anderson Cancer Center (1995), followed by a postdoctoral/research fellowship at the National Institutes of Health (1995–2000). In 2000, he joined the University of Southern California School of Pharmacy, advancing to professor by 2011. He currently leads the Neamati Laboratory at the University of Michigan, focusing on drug design and translational research.

• Ph.D.: University of Texas Graduate School of Biomedical Sciences & M.D. Anderson Cancer Center (1995)
• Postdoctoral Training: NIH (1995–2000)

Research Interests: His lab specializes in structure- and ligand-based drug design, cellular and molecular pharmacology, and preclinical drug development. Key targets include:

• Protein-Protein Interactions (HIV-1 integrase-LEDGF/p75, integrin αvβ3, BCL2, MDM2-p53)
• GPCRs (CXCR2, CXCR4)
• Mitochondrial Agents
• Transcription Factors (STAT3, Nrf2)

Publication Trends: Recent work emphasizes small-molecule degraders, multi-omics approaches in ovarian cancer, and mitochondrial targeting for pancreatic and brain cancers. His chemoinformatic platform includes a library of 10 million compounds with 2 billion 3D conformations and ADMET descriptors.

Scientific Awards:

• NIH Technology Transfer Award (2000)
• GlaxoSmithKline Drug Discovery Award (2002)
• Multiple DOD Concept/Idea Awards (2005–2012)
• LUNGevity Discovery Award (2006)
• Littlefield-AACR Award (2006)

Advising & Grants: As a prolific researcher with 200+ peer-reviewed manuscripts, 18 book chapters, and 30+ patents, he has mentored numerous trainees. He has served on NIH/DOD study sections and held editorial leadership roles in journals including Current Molecular Pharmacology and Journal of Medicinal Chemistry.

Laboratory Infrastructure: The Neamati Lab maintains a 40,000-compound drug-like library, advanced chemoinformatics platforms, and in vitro/in vivo models for mechanistic studies. Their work bridges computational drug design with translational oncology.